NEW YORK – ERS Genomics said on Tuesday that it has signed an agreement with New England Biolabs granting NEB the rights to sell CRISPR-Cas9 tools and reagents from the ERS CRISPR IP portfolio.
Dublin-based ERS Genomics was founded to provide access to CRISPR-Cas9 intellectual property held by Emmanuelle Charpentier. This CRISPR IP is shared between her, Jennifer Doudna and the University of California, and the University of Vienna, and is separate from genome editing patents held by the Broad Institute.